U.S. Tobacco Stock News

In July 2026, SouthState Bank Corporation reported second-quarter results showing net interest income of US$575.95 million, net income of US$230.02 million, net charge-offs of US$8 million (0.06% of average loans), a completed US$247.6 million share repurchase program, and a quarterly dividend increase from US$0.60 to US$0.66 per share, payable August 14, 2026. Together, higher earnings, very low net charge-offs, a larger dividend, and completed buybacks point to management’s confidence in...

Gen Digital recently launched the Fearless Planet Index, a continuously updated cyber safety intelligence hub that uses Gen Threat Labs telemetry to map real-time scams, malware and identity risks across 245 countries and territories. Early Fearless Planet Index insights show phishing dominating global scam activity and reveal sharp country-level differences, giving consumers a localized view of fast-shifting digital risks. With this new real-time Fearless Planet Index showcasing Gen...

Tariff policy is back in the spotlight after court rulings, refunds and fresh import charges have reshaped the cost of bringing goods into the US. For import heavy stocks, the mix of a US$100b refund pool, legal challenges and new tariffs on more than 80 countries creates both relief and fresh risk. Some companies may gain breathing room from extra liquidity, while others face higher input costs and policy uncertainty. This article looks at 3 stocks exposed to these trade developments and how...

Fastly (FSLY) stock is back in focus after the company joined Experian's Agent Trust ecosystem, a collaboration aimed at securing AI driven commerce by verifying AI agents and authorizing their transactions at the network edge. See our latest analysis for Fastly. The Experian partnership arrives at a time when Fastly's share price has gained strong short term momentum, with a 1 day share price return of 8.34%, a 7 day return of 19.95% and a 30 day return of 37.62%. However, the 90 day return...

DexCom (DXCM) drew fresh attention after reporting second quarter 2026 results with higher sales and earnings, and raised full year revenue guidance to a range of about US$5.18b to US$5.25b. See our latest analysis for DexCom. DexCom shares have moved sharply higher in recent weeks, with a 7 day share price return of 16.15% and a 90 day share price return of 44.04%. The 1 year total shareholder return of 15.21% contrasts with weaker 3 and 5 year total shareholder returns. This suggests recent...

In early August 2026, Opera Limited reported 288 million monthly active users for the first quarter, a 25% increase in annualized average revenue per user, and authorized a US$300,000,000 share repurchase program while scheduling its second-quarter 2026 earnings release and call for August 25, 2026. The combination of rising user monetization, expanding AI-powered browser features, and a substantial buyback authorization underscores Opera’s confidence in its business model and capital...

Fortune Brands Innovations recently reported June-quarter results showing non-GAAP earnings per share well above analyst expectations, while revenue came in slightly below consensus amid a low single-digit sales decline. The company also raised its full-year 2026 earnings and operating margin guidance, signaling management’s confidence in improving profitability despite softer top-line trends and a recent senior legal leadership change. With full-year earnings guidance now higher, we'll...

On 6 August 2026, Assured Guaranty Ltd. reported its second-quarter results, with Wall Street having expected consensus earnings of US$1.56 per share, materially above the US$1.01 delivered in the same quarter a year earlier. With investors closely watching loss reserve development, municipal finance business trends, and insured portfolio credit quality, this earnings release highlighted how core underwriting fundamentals may influence how the company is viewed ahead of 2029 analyst...

IMAX stock has delivered very strong gains over the past five years, yet its valuation signals now point in different directions, with a Discounted Cash Flow (DCF) intrinsic value estimate suggesting meaningful upside while earnings based multiples look stretched. That split leaves investors weighing a powerful share price run against mixed signals on what the stock might be worth today. IMAX has returned 252.1% over the past five years. This places recent price moves firmly in the context...

Founder led companies can give you something that is hard to measure but easy to value: leaders with skin in the game who are building long term legacies rather than chasing the next quarter. With global growth signals improving in several developed markets, inflation generally easing in key regions and central banks moving toward steadier policy paths, many investors are looking for management teams that stay focused through economic cycles. This Founder Led Companies screener narrows that...

Zai Lab recently reported that the U.S. FDA granted Orphan Drug Designation to its DLL3-targeting antibody-drug conjugate, zocilurtatug pelitecan (Zoci), for treating neuroendocrine carcinomas, a group of aggressive cancers with limited options. This second orphan designation, following a similar decision in Europe, underlines Zoci’s potential as a first-in-class therapy in a difficult tumor type. We’ll now examine how this new Orphan Drug Designation for Zoci could influence Zai Lab’s...

Alphabet’s surprise AI shakeup has put fresh attention on where leadership and talent sit inside the sector. Jeff Dean and Sanjay Ghemawat are leaving Google to launch a new AI company backed by Alphabet. Demis Hassabis is moving into a chairman and chief scientist role, and Koray Kavukcuoglu is stepping up to run Google’s AI unit and oversee Gemini 4. Alphabet stock fell about 4% after the news. For investors, that kind of disruption can reshape expectations. This article walks through 3 AI...

BETA Technologies (BETA) drew fresh investor attention after announcing plans to expand its financing relationship with the Export Import Bank of the United States, with the potential to secure up to $1b in net funding. See our latest analysis for BETA Technologies. The EXIM financing headlines come after a sharp shift in sentiment around BETA Technologies, with the 1 day share price return of 13.2% and 7 day share price return of 19.5% contrasting with a year to date share price return that...

Symbotic (SYM) heads into its upcoming quarterly earnings report with investor attention on expectations for $0.12 in earnings per share and US$714.76 million in revenue, alongside forecast growth across key warehouse automation segments. See our latest analysis for Symbotic. At a share price of US$47.46, Symbotic has seen a 17.65% 7 day share price return but remains down 26.84% year to date, while the 5 year total shareholder return is about 4x. This indicates short term volatility...

Chemron (CVX) is back in focus after reporting second quarter 2026 results that materially reshaped its income statement. Revenue reached US$70.1b, net income was US$12.1b, and diluted EPS from continuing operations was US$6.11. See our latest analysis for Chevron. Chemron's share price has reacted strongly to the Q2 earnings and dividend news, with a 30 day share price return of 12.53% and a year to date share price return of 22.13%. Over the past year, total shareholder return of 29.62% and...

Why Tyra Biosciences Stock Is Back in Focus After Q2 Results Tyra Biosciences (TYRA) moved into the spotlight after reporting second quarter 2026 results, with a wider net loss and updated timelines for key clinical readouts that could influence how investors view its development pipeline. See our latest analysis for Tyra Biosciences. The second quarter update has arrived during a period where Tyra Biosciences has experienced firm share price momentum, with a 1-month share price return of...

In early August 2026, Keurig Dr Pepper was expected by Wall Street analysts to report past-quarter earnings of US$0.55 per share and revenue of US$7.17 billion, with forecasts also highlighting growth in U.S. Refreshment Beverages and international sales. Analysts also pointed to the integration of the recently acquired JDE Peet's business as a key factor, with potential synergies and international expansion efforts seen as important supports for the company’s performance amid inflation and...

The Cigna Group reported its second-quarter 2026 results, with revenue rising to US$71.67 billion and net income to US$1.66 billion, alongside continued share repurchases under its multiyear buyback program. Despite this growth, recent analyst downgrades have drawn attention to regulatory pressures and uncertainty around Cigna’s pharmacy benefit management operations and business portfolio review. Next, we’ll examine how solid quarterly earnings but heightened PBM and regulatory concerns may...

Tuya Smart recently launched Tuya AI Coding, an AI-native no-code platform that lets non-technical users create and deploy AI-powered lifestyle applications via simple natural-language prompts, fully integrated with Tuya’s global AI+IoT stack and device ecosystem. The ability for Tuya AI Coding to auto-generate full back-end architectures and connect apps to more than 100,000 supported devices could significantly deepen engagement across Tuya’s AI Home ecosystem. Next, we’ll examine how Tuya...

Tennessee completed a statewide cloud migration of its Enterprise Assessment & Tax solution with Tyler Technologies (NYSE:TYL). The project supports nearly 800 users in the Comptroller of the Treasury, Division of Property Assessments. The deployment runs on Amazon Web Services infrastructure and is focused on long term SaaS delivery. The transition is described as one of the largest and most significant statewide cloud moves for this type of system. This Tennessee project places Tyler...

Summit Therapeutics (SMMT) is back in focus after expanding its ivonescimab program with a new global Phase II/III bladder cancer trial, updated survival data in lung cancer, and a kidney cancer collaboration with Arcus Biosciences. See our latest analysis for Summit Therapeutics. The latest ivonescimab updates come after a period where Summit Therapeutics’ share price has been volatile. The 1-year total shareholder return declined 51.75%, and the 3-year total shareholder return was very...

Goodyear Tire & Rubber has seen its share price fall 57.5% over the past five years, yet the stock currently screens as cheap on several valuation checks, which puts the recent weakness in a different light for investors looking at the current price. The share price decline of 57.5% over five years points to a company that the market has been cautious on for an extended period, which can sometimes leave valuations disconnected from underlying fundamentals. The planned closure of the...

CME Group stock has delivered a 55.1% gain over the past five years, yet current valuation checks and pricing signals suggest the shares may now sit closer to fair value rather than being a clear bargain. Recent product launches and record activity in key contracts are drawing attention, while the intrinsic value estimate and market multiples offer a more restrained read on potential upside. A 55.1% return over five years points to solid long term wealth creation, which raises the bar for...

Aramark (ARMK) shares are in focus after the company confirmed a quarterly dividend of $0.12 per share and announced a new long-term campus dining partnership with the University of Colorado Colorado Springs. See our latest analysis for Aramark. At a share price of $56.22, Aramark has seen short term momentum ease with the 7 day share price return down 2.06%, although the 90 day share price return of 22.80% and 5 year total shareholder return of 141.27% show a much stronger longer term...